Immutep Says Nearly 300 Patients Enrolled for Lung Cancer Trial

MT Newswires Live

Dec 16, 2025

Immutep (ASX:IMM) said the registrational TACTI-0004 third phase trial, evaluating its drug candidate eftilagimod alfa in combination with Merck's anti-PD-1 therapy Keytruda and chemotherapy, as a first-line treatment for advanced or metastatic non-small cell lung cancer, enrolled 289 patients globally, according to a Tuesday Australian bourse filing.

It has enrolled over 38% of the trial's target of 756 patients, and its number of activated clinical sites is now over 120. It expects to complete patient enrollment in the third quarter of 2026.

The firm's shares fell 1% in recent trading on Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2591967586"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2591967586\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2591967586?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 08:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591967586","market":"sg","top_or_hot":-1,"title":"Immutep Says Nearly 300 Patients Enrolled for Lung Cancer Trial","media":"MT Newswires Live","content":"<html><body><p> Immutep (ASX:IMM) said the registrational TACTI-0004 third phase trial, evaluating its drug candidate eftilagimod alfa in combination with Merck's anti-PD-1 therapy Keytruda and chemotherapy, as a first-line treatment for advanced or metastatic non-small cell lung cancer, enrolled 289 patients globally, according to a Tuesday Australian bourse filing.</p><p>It has enrolled over 38% of the trial's target of 756 patients, and its number of activated clinical sites is now over 120. It expects to complete patient enrollment in the third quarter of 2026.</p><p>The firm's shares fell 1% in recent trading on Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep Says Nearly 300 Patients Enrolled for Lung Cancer Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep Says Nearly 300 Patients Enrolled for Lung Cancer Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-16 08:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Immutep (ASX:IMM) said the registrational TACTI-0004 third phase trial, evaluating its drug candidate eftilagimod alfa in combination with Merck's anti-PD-1 therapy Keytruda and chemotherapy, as a first-line treatment for advanced or metastatic non-small cell lung cancer, enrolled 289 patients globally, according to a Tuesday Australian bourse filing.</p><p>It has enrolled over 38% of the trial's target of 756 patients, and its number of activated clinical sites is now over 120. It expects to complete patient enrollment in the third quarter of 2026.</p><p>The firm's shares fell 1% in recent trading on Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMM.AU","symbol_name":"IMMUTEP LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2591967586","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591967586","pubTimestamp":1765846096,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Immutep  said the registrational TACTI-0004 third phase trial, evaluating its drug candidate eftilagimod alfa in combination with Merck's anti-PD-1 therapy Keytruda and chemotherapy, as a first-line treatment for advanced or metastatic non-small cell lung cancer, enrolled 289 patients globally, according to a Tuesday Australian bourse filing.It has enrolled over 38% of the trial's target of 756 patients, and its number of activated clinical sites is now over 120. It expects to complete patient enrollment in the third quarter of 2026.The firm's shares fell 1% in recent trading on Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMM.AU":"IMMUTEP LTD","BK7508":"医药生物股","BK7067":"生物科技"},"translate_title":"Immutep称近300名患者参加了肺癌试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMM.AU":1},"content_text":"Immutep (ASX:IMM) said the registrational TACTI-0004 third phase trial, evaluating its drug candidate eftilagimod alfa in combination with Merck's anti-PD-1 therapy Keytruda and chemotherapy, as a first-line treatment for advanced or metastatic non-small cell lung cancer, enrolled 289 patients globally, according to a Tuesday Australian bourse filing.It has enrolled over 38% of the trial's target of 756 patients, and its number of activated clinical sites is now over 120. It expects to complete patient enrollment in the third quarter of 2026.The firm's shares fell 1% in recent trading on Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}